Results 1 to 10 of about 2,439,262 (338)

Role of adrenergic receptors in shock [PDF]

Frontiers in Physiology, 2023
Shock is a severe, life-threatening medical condition with a high mortality rate worldwide. All four major categories of shock (along with their various subtypes)—hypovolemic, distributive, cardiogenic, and obstructive, involve a dramatic mismatch ...
Mathew Geevarghese, Krishna Patel, Anil Gulati, Anil Gulati, Anil Gulati, Amaresh K. Ranjan   +5 more
doaj   +4 more sources

Ligands of Adrenergic Receptors: A Structural Point of View

Biomolecules, 2021
Adrenergic receptors are G protein-coupled receptors for epinephrine and norepinephrine. They are targets of many drugs for various conditions, including treatment of hypertension, hypotension, and asthma.
Yiran Wu, Liting Zeng, Suwen Zhao
doaj   +2 more sources

α1-Adrenergic Receptors in Neurotransmission, Synaptic Plasticity, and Cognition

Frontiers in Pharmacology, 2020
α1-adrenergic receptors are G-Protein Coupled Receptors that are involved in neurotransmission and regulate the sympathetic nervous system through binding and activating the neurotransmitter, norepinephrine, and the neurohormone, epinephrine.
Dianne M. Perez
doaj   +2 more sources

ADRENERGIC RECEPTORS IN CORONARY ARTERIES* [PDF]

Annals of the New York Academy of Sciences, 1967
Peer Reviewed ; http://deepblue.lib.umich.edu/bitstream/2027.42/72463/1/j.1749-6632.1967.tb41248.x ...
David F. Bohr
openaire   +5 more sources

Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.

PLoS ONE, 2013
Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable efficacy in the treatment of benign vascular tumors such as infantile hemangiomas.
Jessica M Stiles, Clarissa Amaya, Steven Rains, Dolores Diaz, Robert Pham, James Battiste, Jaime F Modiano, Victor Kokta, Laura E Boucheron, Dianne C Mitchell, Brad A Bryan   +10 more
doaj   +2 more sources

Deciphering the Role of Adrenergic Receptors in Alzheimer’s Disease: Paving the Way for Innovative Therapies [PDF]

Biomolecules
Neurodegenerative diseases are currently among the most devastating diseases with no effective disease-modifying drugs in the market, with Alzheimer’s disease (AD) being the most prevalent.
Androulla N. Miliotou, Andria Kotsoni, Lefteris C. Zacharia   +2 more
doaj   +2 more sources

Comparative Study of the Effects of Drugs Targeting Adrenergic Receptors on the Early Life Stages of Zebrafish [PDF]

Toxics
Owing to the presence of drugs targeting adrenergic receptors in aquatic ecosystems, considerable attention has been directed towards their environmental distribution and fate in recent decades.
Junsheng Lv, Fengzhu Sun, Zaitian Li, Yueyun Qin, Ruozhu Sheng, Liwei Sun   +5 more
doaj   +2 more sources

Selectivity and Maximum Response of Vibegron and Mirabegron for β3-Adrenergic Receptors

Current Therapeutic Research, 2022
: Background: The β3-adrenergic agonists vibegron and mirabegron have shown favorable safety profiles and efficacy for the treatment of overactive bladder.
Benjamin M. Brucker, MD, Jennifer King, PharmD, Paul N. Mudd, Jr, PharmD, MBA, Kimberly McHale, PhD   +3 more
doaj   +1 more source

Biased, Bitopic, Opioid–Adrenergic Tethered Compounds May Improve Specificity, Lower Dosage and Enhance Agonist or Antagonist Function with Reduced Risk of Tolerance and Addiction

Pharmaceuticals, 2022
This paper proposes the design of combination opioid–adrenergic tethered compounds to enhance efficacy and specificity, lower dosage, increase duration of activity, decrease side effects, and reduce risk of developing tolerance and/or addiction ...
Robert Root-Bernstein
doaj   +1 more source

Co-Evolution of Opioid and Adrenergic Ligands and Receptors: Shared, Complementary Modules Explain Evolution of Functional Interactions and Suggest Novel Engineering Possibilities

Life, 2021
Cross-talk between opioid and adrenergic receptors is well-characterized and involves second messenger systems, the formation of receptor heterodimers, and the presence of extracellular allosteric binding regions for the complementary ligand; however ...
Robert Root-Bernstein, Beth Churchill
doaj   +1 more source